Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate.

Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate.

Publication date: Mar 11, 2019

The severe motor impairment in the MS animal model experimental autoimmune encephalomyelitis (EAE) obstructs the assessment of cognitive functions. We developed an experimental system that evaluates memory faculties in EAE-affected mice, irrespective of their motor performance, enabling the assessment of cognitive impairments along the disease duration, the associated brain damage, and the consequences of glatiramer acetate (GA) treatment on these manifestations. The delayed-non-matching to sample (DNMS) T-maze task, testing working and long term memory was adapted and utilized. Following the appearance of clinical manifestations task performances of the EAE-untreated mice drastically declined. Cognitive impairments were associated with disease severity, as indicated by a significant correlation between the T-maze performance and the clinical symptoms in EAE-untreated mice. GA-treatment conserved cognitive functions, so that despite their exhibited mild motor impairments, the treated mice performed similarly to nacEFve controls. The cognitive deficit of EAE-mice coincided with inflammatory and neurodegenerative damage to the frontal cortex and the hippocampus; these damages were alleviated by GA-treatment. These combined findings indicate that in addition to motor impairment, EAE leads to substantial impairment of cognitive functions, starting at the early stages and increasing with disease aggravation. GA-treatment, conserves cognitive capacities and prevents its disease related deterioration.

Open Access PDF

Aharoni, R., Schottlender, N., Bar-Lev, D.D., Eilam, R., Sela, M., Tsoory, M., and Arnon, R. Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate. 17498. 2019 Sci Rep (9):1.

Concepts Keywords
Brain Damage Cognitive deficit
Cognitive Post-chemotherapy cognitive impairment
Cognitive Deficit Delirium
Cognitive Impairment Health
Correlation Medical specialties
Frontal Cortex Medicine
Glatiramer Acetate Cognitive disorders
Hippocampus Impairment multiple sclerosis
Maze
Memory
Mice
Multiple Sclerosis
Nave
Neurodegenerative
Sci

Semantics

Type Source Name
gene UNIPROT KCNK3
gene UNIPROT MAGEE1
disease MESH experimental autoimmune encephalomyelitis
drug DRUGBANK Glatiramer
disease DOID multiple sclerosis
disease MESH multiple sclerosis
disease MESH Cognitive impairment
disease MESH atrophy
disease MESH demyelination
disease MESH CNS disease
gene UNIPROT NR1H4
gene UNIPROT ADRB2
gene UNIPROT BFAR
drug DRUGBANK Coenzyme M
disease DOID anxiety
disease MESH anxiety
disease MESH paralysis
gene UNIPROT MOG
gene UNIPROT TSPO
gene UNIPROT CHRM3
gene UNIPROT TNFRSF11A
gene UNIPROT NOVA2
gene UNIPROT ARMC9
gene UNIPROT AKR1A1
gene UNIPROT DEPP1
gene UNIPROT GOPC
disease MESH memory deficits
disease DOID neurodegenerative disease
disease MESH neurodegenerative disease
drug DRUGBANK 1-naphthaleneacetic acid
gene UNIPROT CYREN
pathway BSID Brain derived neurotrophic factor
gene UNIPROT DMTN
disease DOID encephalomyelitis
disease MESH encephalomyelitis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *